• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cadrenal Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    3/4/25 8:05:23 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVKD alert in real time by email
    false 0001937993 0001937993 2025-03-03 2025-03-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported): March 3, 2025

     

    Cadrenal Therapeutics, Inc.

    (Exact name of registrant as specified in charter)

     

    Delaware   001-41596   88-0860746
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    822 A1A North, Suite 306

    Ponte Vedra, Florida 32082

    (Address of principal executive offices and zip code)

     

    (904) 300-0701

    (Registrant’s telephone number including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   CVKD   The Nasdaq Stock Market LLC
    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On March 3, 2025, Cadrenal Therapeutics, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) with Abbott Global Enterprises Limited (“Abbott”) to collaborate on the Phase 3 randomized, warfarin-controlled, multicenter study with an open-label extension being sponsored by the Company, named “TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices” (the “Study”), to evaluate the efficacy and safety of tecarfarin in patients with a left-ventricular assist device (“the “Study Device”).

     

    Pursuant to the Collaboration Agreement, Abbott will share with the Company data collected by it on the LVAD population via its MOMENTUM 3 and ARIES HM3 US IDE trials and further grant the Company a non-exclusive, limited, non-transferable, non-sublicensable license to use the data for the purposes of the Company’s Study, including support for protocol development, as well as regulatory submissions related to the Study. The Company shall be the regulatory sponsor of the Study and shall have the obligations of the sponsor pursuant to applicable laws, including, without limitation, monitoring of the Study and interacting with regulatory authorities with respect to the Study. The Company is pursuing business development strategies, including licenses and funding partnerships, to support funding the Phase 3 study.

     

    The Collaboration Agreement further provides that the Company and Abbott will collaborate in the following areas: (1) Biostatistics including Statistical Analysis Plan development, (2) Site and investigator selection, (3) Site qualification/feasibility, (4) Patient identification and recruitment, and (5) Medical science liaison support.

     

    The Collaboration Agreement provides that the Company will own the Study data and grant Abbott a non-exclusive, royalty-free license to use the Study data for research and development purposes relating to Abbott’s products. The Collaboration Agreement further provides that intellectual property unrelated to the Study Device that is conceived, first reduced to practice or created solely by the Company in connection with the Study pursuant to the Collaboration Agreement, will be the sole property of the Company and intellectual property unrelated to tecarfarin that is conceived, first reduced to practice or created solely by Abbott in connection with the Study pursuant to the Collaboration Agreement, will be the sole property of the Abbott. The Collaboration Agreement also provides that intellectual property conceived, first reduced to practice or created by either Abbott or the Company as a result of or in connection with the Study under the Collaboration Agreement, and that (i) uses, incorporates, or directly relates to tecarfarin, and (ii) does not use, incorporate, or directly relate to the Study Device will be the sole property of the Company. Any intellectual property conceived, first reduced to practice or created by either Abbott or the Company in connection with the Study pursuant to the Collaboration Agreement, and that uses, incorporates, or otherwise directly relates to the Study Device and does not use, incorporate, or directly relate to tecarfarin will be the sole property of Abbott. The Collaboration Agreement further provides that the data from the Study may not be used by Abbott to develop or commercialize any other anticoagulant except when working on the Study Device.

     

    Either party may terminate the Collaboration Agreement without cause upon sixty days written notice to the other party and immediately upon a material breach by the other party of any provision of the Collaboration Agreement.

     

    The foregoing description of the Collaboration Agreement does not purport to be complete and is qualified in its entirety by reference to the Collaboration Agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated by reference herein.

     

    Item 8.01. Other Events.

     

    On March 4, 2025, the Company issued a press release announcing the entry into the Collaboration Agreement above. The press release issued in connection with this announcement is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

     

    1

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    The following exhibits are furnished with this Current Report on Form 8-K:

     

    Exhibit
    Number
      Exhibit Description
         
    10.1   Collaboration Agreement between Abbott Global Enterprises Limited and Cadrenal Therapeutics, Inc.
    99.1   Press Release, issued by Cadrenal Therapeutics, Inc. on March 4, 2025
    104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: March 4, 2025 CADRENAL THERAPEUTICS, INC.
       
      By: /s/ Quang Pham
      Name:  Quang Pham
      Title: Chairman and Chief Executive Officer

     

     

    3

     
    Get the next $CVKD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVKD

    DatePrice TargetRatingAnalyst
    12/18/2023$4.00Outperform
    Noble Capital Markets
    More analyst ratings

    $CVKD
    Financials

    Live finance-specific insights

    See more
    • Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

      Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of

      3/13/25 4:05:00 PM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    SEC Filings

    See more
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 4:05:33 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cadrenal Therapeutics Inc.

      10-Q - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 6:17:43 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      4/17/25 6:12:02 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Cadrenal Therapeutics with a new price target

      Noble Capital Markets initiated coverage of Cadrenal Therapeutics with a rating of Outperform and set a new price target of $4.00

      12/18/23 8:12:12 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

      Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE:ABT) validates the need for new anticoagulation options Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin. "In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024," sa

      5/8/25 8:00:00 AM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

      Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced that Chairman and CEO Quang X. Pham will present at the inaugural Centri Capital Conference, to be held at Nasdaq in New York City on April 22, 2025. Mr. Pham will deliver a company overview and provide updates on the development of tecarfarin, Cadrenal's lead asset, addressing unmet needs in anticoagulation therapy. The Centri Capital Conference will feature attendees from across the capital markets and investment community, connecting with executives from companies shaping the future of he

      4/17/25 9:40:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

      Management Available for One-to-One Meetings Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company's commitment to advancing innovation and clinical development in anticoagulation therapy. Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18th National Conference on Anticoagulation Therapy in Washington, D.C. from April 3-5, engaging with leading experts and ke

      4/3/25 8:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by CEO and Chairman Pham Quang X

      4/A - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      3/24/25 8:38:14 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Ferguson James J. Iii

      4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      2/6/25 4:51:35 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Ferguson James J. Iii

      3 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      2/6/25 4:50:29 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cadrenal Therapeutics Inc.

      SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

      11/14/24 4:00:17 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cadrenal Therapeutics Inc.

      SC 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

      10/4/24 4:15:02 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Leadership Updates

    Live Leadership Updates

    See more
    • Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

      James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development opportunities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K antagonist, today announced a leadership transition appointing James J. Ferguson, MD, FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson is a distinguished medical expert with over 25

      2/6/25 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

      Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. Quang X. Pham, Chairman and Chief

      12/18/24 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

      PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin. Mr. Cole brings over 25 years of

      2/8/24 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care